Healthcare Services APAC

APAC Prediabetes Management Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Prediabetes Management Market Industry Trends and Forecast to 2034: Segmented by (Approach, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $997.2 Mn Placeholder estimate
Estimate 2025 $1.10 Bn 22.1% of the global market
Projected 2034 $2.68 Bn 143.6% Adds $1.58 Bn over 9 forecast years
CAGR 2025–2034 10.4% Faster than 50% of 107 Healthcare Services markets here
Key players 5
  • APAC is 22.06% of the global market.
  • Among regions, the largest is North America at $2.78 Bn.
  • Fastest growing: Africa at 10.8% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.58 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Prediabetes Management Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $997.2 Mn — —
2025 (base) $1.10 Bn +$103.7 Mn —
2026 (forecast) $1.22 Bn +$114.5 Mn +10.4%
2027 (forecast) $1.34 Bn +$126.4 Mn +21.9%
2028 (forecast) $1.48 Bn +$139.6 Mn +34.6%
2029 (forecast) $1.64 Bn +$154.1 Mn +48.6%
2030 (forecast) $1.81 Bn +$170.1 Mn +64%
2031 (forecast) $1.99 Bn +$187.8 Mn +81.1%
2032 (forecast) $2.20 Bn +$207.3 Mn +99.9%
2033 (forecast) $2.43 Bn +$228.9 Mn +120.7%
2034 (forecast) $2.68 Bn +$252.7 Mn +143.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Prediabetes Management Market Analysis at a glance
Market size, 2025$1.10 Bn placeholder estimate
Forecast, 2034$2.68 Bn placeholder estimate
Growth (CAGR), 2025–203410.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApproach, setting and end user (see all)
Key playersOmada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA, Teladoc Health (see all)
Active clinical trials39 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Prediabetes Management Market Analysis Executive Summary

Prediabetes management covers tests, programs, medicines and digital tools that help people with raised blood sugar avoid type 2 diabetes.

Key segments of the prediabetes Management market include approach (Lifestyle Programs, Medication and Digital Coaching) and setting (Primary Care, Workplace Programs and Home).

Bar chart: Asia Pacific Prediabetes Management market size, 2024–2034, placeholder estimates. $997.2 Mn in 2024, $1.10 Bn in 2025 and $2.68 Bn in 2034, 10.4% CAGR.
Asia Pacific Prediabetes Management market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Prediabetes Management Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the prediabetes Management market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the prediabetes Management market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Prediabetes Management Market in APAC

The prediabetes Management market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Prediabetes Management Market in APAC

Prediabetes Management in APAC: payment and research

How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[1], basic medical insurance (China)⁠[2], the Hospital Authority (Hong Kong)⁠[3], Ayushman Bharat PM-JAY (India)⁠[4], public health insurance (Japan)⁠[5], subsidised public care (Malaysia)⁠[6], Pharmac (New Zealand)⁠[7], PhilHealth (Philippines)⁠[8], MediShield Life (Singapore)⁠[9], the Universal Coverage Scheme (Thailand)⁠[10], JKN (BPJS Kesehatan) (Indonesia)⁠[11], out of pocket and Sehat Sahulat (Pakistan)⁠[12], National Health Insurance (South Korea)⁠[13] and social health insurance (Vietnam)⁠[14]. ClinicalTrials.gov lists 39 studies on Prediabetes Management that are recruiting, active or about to start in APAC.⁠[15]

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] Hospital Authority. Checked 14 Nov 2026.

[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[6] Ministry of Health Malaysia. Checked 14 Nov 2026.

[7] Pharmac. Checked 14 Nov 2026.

[8] PhilHealth. Checked 14 Nov 2026.

[9] CPF Board, MediShield Life. Checked 14 Nov 2026.

[10] National Health Security Office. Checked 14 Nov 2026.

[11] BPJS Kesehatan. Checked 19 Nov 2026.

[12] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[13] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[14] Vietnam Social Security. Checked 19 Nov 2026.

[15] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how prediabetes Management services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Prediabetes Management right now, from free public sources.

Clinical trials

39 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Signos 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Afghanistan25.32022
Australia8.12022
Bangladesh17.92022
China11.22022
India22.62022
Indonesia12.82022
Japan6.42022
Malaysia26.72022
Myanmar13.82022
Nepal15.82022
New Zealand9.02022
Pakistan30.92022
Philippines13.22022
Singapore13.12022
South Korea10.42022
Thailand12.32022
Vietnam10.92022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Prediabetes Management in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Prediabetes Management market in Asia Pacific?
Placeholder estimate: about $1.10 Bn in 2025, rising to about $2.68 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Prediabetes Management market in Asia Pacific growing?
Placeholder estimate: about 10.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Prediabetes Management market report cover?
The report splits the market by approach (Lifestyle Programs, Medication, Digital Coaching, Screening and Testing), setting (Primary Care, Workplace Programs, Home) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Prediabetes Management market?
Key players include Omada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA and Teladoc Health.
What is driving the Prediabetes Management market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market.
How many clinical trials on Prediabetes Management are running in Asia Pacific?
39 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Prediabetes Management?
PubMed lists 57 papers on Prediabetes Management added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in APAC

See all

Related on diabetes and obesity

See the topic